Innovationen for a
We supply the keys to new therapies
Antibody Drug Conjugates (ADCs) are a new approach in the development of innovative drugs for cancer therapy. This fundamental technology has already been described in 1908 by Paul Ehrlich and awarded with the Nobel Prize in Medicine. Human antibodies are coupled to highly potent toxins (conjugation) to selectively kill cancer cells and facilitate healing. This technology also reduces side effects.
Leading biotech and pharmaceutical companies rely on Cfm Oskar Tropitzsch GmbH in the sustainable sourcing of toxins as payloads for ADCs – including substances with IC50 values in the picomolar range and novel or special mode of action.
Another challenge is the worldwide logistic of highly-potent products, to meet all country-specific requirements. The active exchange with ADC experts worldwide enables us to offer additional services: we provide conjugation partners, contract manufacturing specialists and safety rating experts.
Our service includes the active marketing of potential payload candidates, often discovered by innovative start-ups. The „young savages“ see in the marketing of their substances the clear advantage of having access to the existing, dense global Cfm network.
The Cfm-Team would like to make your life easier and therefore we provide a SD-File which includes all payloads and reagents for Antibody Drug Conjugation (ADC).
Cfm Oskar Tropitzsch GmbH supplies unique molecules as payloads for ADCs.
These payloads are highly and ultra-toxic drugs, i.e. cytotoxic and/or cytostatic molecules, effective at a low dosage and therefore classified as highly potent APIs (HPAPIs)
The Poison of the green death cap mushroom
Alpha-Amanitin for ADC Applications
We are active in the product segment of Antibody Drug Conjugates since 2014 and are mainly working on the payload side. First substances were quickly established in the market. As a competent partner, Cfm Oskar Tropitzsch GmbH was soon asked for alpha-amanitin, the highly potent poison of the green death cap mushroom, which is acting in the picomolar range.
Toxins generally require special treatment; but such poisons were something special even for us. Our team led by Michael Schäffler bundled the know-how, found trustworthy sources and solutions for secure logistics right up to the first customers on the US West Coast.
After research and due diligence, we found a highly qualified manufacturer in Europe who had been working with alpha-amanitin for several years and perfected the extraction from the green death cap mushroom. The challenges were that green dash cap mushrooms can not be cultivated and about one gram of alpha-amanitin requires about 20 kilograms of fresh, wild collected mushrooms. We had inquiries for more than 10 grams, and the tendency was increasing.
To find a solution, our team became creative: we wondered if the production of alpha-amanitin would be possible by fermentation. Such a process could equalize the supply bottleneck, lower the price and thus accelerate research at universities and research institutions.
Michael Schäffler used his contacts, explained challenges, set transparency in the market overview and convinced a long-time Cfm partner company of the project.
A detailed consideration of risk and potential resulted in an „Go“ for the screening to find the right strain. Not even six months after the launch of this project, we were able to safely supply alpha-amanitin by fermentation. Our partner established a reproducible process for production and purification. With a significantly reduced price, we took responsiblity for our clients in order to speed up research to cure patients.
Senior Project Manager
Project of the year 2016
Winner of the Bavarian Export Prize in the field of Services